Literature DB >> 442179

Immunity of cholera in man: relative role of antibacterial versus antitoxic immunity.

M M Levine, D R Nalin, J P Craig, D Hoover, E J Bergquist, D Waterman, H P Holley, R B Hornick, N P Pierce, J P Libonati.   

Abstract

Purified cholera toxoid is antigenic when given enterally and orally. Purified toxoid fails to provide protection against experimental challenge. Clinical cholera confers formidable protection against homologous or heterologous rechallenge. Failure to culture vibrios from intestinal fluid or stool of re-challenge volunteers suggests that the predominant immune mechanism is antibacterial rather than antitoxic.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 442179     DOI: 10.1016/0035-9203(79)90119-6

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  62 in total

1.  Interaction of Vibrio cholerae cells with beta-lactam antibiotics: emergence of resistant cells at a high frequency.

Authors:  T K Sengupta; K Chaudhuri; S Majumdar; A Lohia; A N Chatterjee; J Das
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

2.  Vibrio cholerae-induced inflammation in the neonatal mouse cholera model.

Authors:  Anne L Bishop; Bharathi Patimalla; Andrew Camilli
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

3.  Serotype cycles in cholera dynamics.

Authors:  Katia Koelle; Mercedes Pascual; Md Yunus
Journal:  Proc Biol Sci       Date:  2006-11-22       Impact factor: 5.349

4.  Immunochemical characterization of synthetic hexa-, octa- and decasaccharide conjugate vaccines for Vibrio cholerae O:1 serotype Ogawa with emphasis on antigenic density and chain length.

Authors:  Peter Ftacek; Victor Nelson; Shousun C Szu
Journal:  Glycoconj J       Date:  2013-08-17       Impact factor: 2.916

5.  Hemagglutination is a novel biological function of lipopolysaccharide (LPS), as seen with the Vibrio cholerae O139 LPS.

Authors:  M Alam; S Miyoshi; K Tomochika; S Shinoda
Journal:  Clin Diagn Lab Immunol       Date:  1997-09

Review 6.  The immunopathology of M cells.

Authors:  I C Davis; R L Owen
Journal:  Springer Semin Immunopathol       Date:  1997

7.  Preliminary assessment of the safety and immunogenicity of live oral cholera vaccine strain CVD 103-HgR in healthy Thai adults.

Authors:  S Migasena; P Pitisuttitham; B Prayurahong; P Suntharasamai; W Supanaranond; V Desakorn; U Vongsthongsri; B Tall; J Ketley; G Losonsky
Journal:  Infect Immun       Date:  1989-11       Impact factor: 3.441

8.  Weak serum and intestinal antibody responses to Vibrio cholerae soluble hemagglutinin in cholera patients.

Authors:  A M Svennerholm; M M Levine; J Holmgren
Journal:  Infect Immun       Date:  1984-09       Impact factor: 3.441

9.  Enhanced mucosal priming by cholera toxin and procholeragenoid with a lipoidal amine adjuvant (avridine) delivered in liposomes.

Authors:  N F Pierce; J B Sacci
Journal:  Infect Immun       Date:  1984-05       Impact factor: 3.441

10.  Assay dependent specificities of monoclonal antibodies to bacterial antigens.

Authors:  S Ghosh; A M Campbell
Journal:  Clin Exp Immunol       Date:  1986-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.